lack earn visibl make hard mylan still built last
invest summari reiter neutral rate pt
follow ep miss lower-than-expect guidanc lack
earn visibl keep us sidelin could still
becom construct stock new product opportun exceed
expect and/or gener drug price improv
takeaway quarter ow
announc posit new data multipl yupelri studi treatment
copd fda approv yupelri
court appeal affirm decis teva neutral copaxon
mg/ml dose patent invalid announc
 launch medroxyprogesteron acet inject suspens usp
mg/ml single-dos vial gener version ow depo-
provera biocon nc announc ema
chmp issu posit opinion recommend approv ogivri
biosimilar rhhbi cover herceptin addit initi
commerci launch hulio major european market biosimilar
implement comprehens restructur remedi plan
morgantown facil light wl issu fda addit
voluntari nationwid recal valsartan-contain product issu due
detect trace amount ndea receiv fda
approv anda gener version takeda nc prevacid
solutab dr date also expand recal includ
lot valsartan-contain product within expiri ad
first gener version neutral canasa treatment ulcer
proctiti gener version shpg ow lialda uc result
affect lower-than-expect uptak gener copaxon lack
approv gener advair
 report ep factset consensu
estim releas ep guidanc
first time factset consensu updat financi model
outlook result decreas ep
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti upsid downsid risk neutral invest thesi
risk downsid includ follow gener drug price continu declin
could come increas competit key product also custom
consolid given buy consortium power negoti better price
consortium could continu caus price fall although integr meda
progress integr fall behind rel expect could pressur
stock harder follow progress meda divis
gener lot public data avail report
quarter lack meaning gener launch could make hard
off-set sale declin matur product gener industri product shorter
life cycl brand drug gener part commod busi
risk upsid includ follow could receiv approv launch
advair and/or restasi year one combin product could provid
upsid potenti consensu expect would limited-opportun larg gener
opportun integr meda could progress faster expect higher amount
synergi captur faster synergi captur could drive upsid number mylan
brand drug biosimilar busi may move forward new product
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull-
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casegener drug price improvesgener drug launch expectationsbiosimilarslaunch scenario casegener drug price stablegener drug launch in-lin expectationsbiosimilarslaunch in-lin scenario casegener drug price declin furthergener drug launch expectationsbiosimilarslaunch scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot gross time oper non oper pre-tax tax non-oper items- nm- nm- net averag oper cantor fitzgerald research compani estim exhibit catalyst event calendar
datedriverupcom biosimilar restasisu biosimilar insulin aspart initi phase type year old fall gener royalti bear licens earli herceptin trastuzumab biosimilarlaunch settlement date advair submit eu depotind file initi phase estrogen gx premarin meet flixotid pmdieu submit per settlement ag biosimilar insulin glargin end biosimilar insulin aspart phase data type depotnda submiss late stay botoxapprov biosimilar adalimumab earliest possibl launch per patent licens revefenacin exclus linzess mcg mcg launch per settlement linzess mcg launch per settlement agnaugust depotu patent expiresourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
million except ep compound-annual-growth-rate year end decemb gross oper non-oper pre-tax tax minor interest net averag oper changetot cantor fitzgerald research compani report exclud purchas account relat amort litig settlement amort convert debt discount conting consider liabil clean energi invest acquisit relat cost restructur special item relat tax effect exclud purchas account amort litig settlement clean energi interest expens invest loss accret conting consider acquisit relat custom incent restructur relat cost special item relat tax effect adjust exclud purchas account amort litig settlement clean energi interest expens invest loss interest expens accret conting considerationli fair valu adjust acquisit relat cost restructur relat cost special item tax effect relat adjust exclud purchas account relat amort litig settlement conting interest expens clean energi invest financ accret conting consider clean energi invest pre-tax loss acquisit relat cost restructur relat cost special item relat tax effect relat adjust exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb total changetot cantor fitzgerald research compani reportsspecialti includ brand revenu includ author gener product sale exhibit annual sale analysi
fiscal gener paragraph paragraph iv exclus opp risk-adjust acetylcystein acetadot inject nmnmnmnmnmnmnmnmnmpioglitazon actoplu olmesartan celebrex nmnmnmnmnmnmnmnmnmvareniclin chantix nmnmnmnmnmnmnmnmnmdesloratadin delayed-releas capsul chewabl inject hectorol kaletra nmnmnmnmnmnmnmnmnmpregabalin transderm system acid tablet dr sodium phosphat orapr extend releas prezista nmnmnmnmnmnmnmnmnmmilnacipran ethinyl estradiol silenor nmnmnmnmnmnmnmnmnmniacin extend release/simvastatin strattera nmnmnmnmnmnmnmnmnmsunitinib malat hcl treximet nmnmnmnmnmnmnmnmnmsildenafil citrat tablet tablet dimesyl piv cumul paragraph iv non-u asset global institut busi bionich gener cantor fitzgerald research compani report bold italic mean settlement exhibit analysi
million decemb fiscal activitiesnet non-cash chang work capit net activitiesproce purchas capit sale sale market item net activitieslong-term oblig option proce purchas common net cash exchang balanc balanc cantor fitzgerald research compani report exhibit balanc sheet analysi
million decemb fiscal cash market securities- account receiv inventori defer incom tax prepaid expens current total current properti plant equip intang asset total liabil sharehold equitytrad account incom tax current portion long-term dividend payable- current total current long term total common prefer addit paid retain less common stock treasuri total sharehold total liabil sharehold sourc cantor fitzgerald research compani report compani descript
global pharmaceut compani develop licens manufactur market distribut gener brand name over-
the-count over-the-counter product varieti dosag form therapeut categori product portfolio includ approxim
product compani market countri territori
price close feb
analyst primarili respons research report whose name appear front cover certifi view express
research report accur reflect person view subject secur issuer featur report ii part
research analyst compens directli indirectli relat specif recommend view express
research analyst report
invest bank next month cantor fitzgerald and/or affili expect receiv intend seek compens invest bank
servic within next three month compani referenc within report
cantor fitzgerald and/or affili market maker inc
cantor fitzgerald and/or affili market maker allergan inc
cantor fitzgerald and/or affili market maker inc
lead co-manag cantor fitzgerald and/or affili act lead co-manag public offer equiti and/or debt secur
therav biopharma inc within last month
invest bank last month cantor fitzgerald and/or affili receiv compens invest bank servic last month
cantor fitzgerald and/or affili market maker therav biopharma inc
cantor fitzgerald and/or affili market maker teva ind ltd
overweight/ow analyst expect stock total return stock price appreci plu dividend outperform rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month overweight rate equat buy rate
neutral analyst expect stock total return stock price appreci plu dividend perform line rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month neutral rate equat hold rate
underweight/uw analyst expect stock total return stock price appreci plu dividend under-perform rel analyst
broadli defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month underweight rate equat sell rate
covered/nc cantor fitzgerald provid invest opinion provid research coverag stock
rated/nr current carri rate stock rate estim review nr rate equat overweight
neutral underweight rate thu count calcul percentag subject compani within three categori
cantor fitzgerald provid invest bank servic within previou month
report inform purpos base publicli avail data believ reliabl represent made data
accur complet opinion project contain herein reflect opinion date report subject chang pursuant
cantor fitzgerald polici author report share compani he/sh cover
cantor fitzgerald cantor fitzgerald logo trademark regist trademark cantor fitzgerald secur affili
countri trademark appear herein properti respect owner neither cantor fitzgerald secur affili
associ affili third parti
materi present sole institut commun meant view complet fundament analysi secur
materi may offer recommend strategi shorter term natur materi contain analysi may narrowli focus
may base either pure quantit model uniqu factor market supply/demand factor surround potenti market move
event make invest decis inform view one factor invest decis process past perform
taken indic guarante futur result
disclosur uk investor
